← Leaderboards
Uday B Kompella
University Of Nebraska Medical Center
$10,057,327
Attributed
$14,815,449
Total exposure
16
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,805,712 · 14
FDA$1,009,737 · 2
By mechanism
R01$11,366,881 · 7
R21$1,692,483 · 4
U01$1,009,737 · 2
R03$441,000 · 1
R41$271,468 · 1
R13$33,880 · 1
Top collaborators
- Anuj Chauhan7 shared
- Todd C Carpenter4 shared
- Eva Nozik Grayck4 shared
- Mark R Prausnitz4 shared
- Carmen C Sucharov4 shared
- Hu Yang3 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- David B Bylund$2,535,571
Others in their field
Top investigators on “Drug Delivery Systems”
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Gerald Van Belle · University Of Washington$48,120,734
- David Heimbrook · Leidos Biomedical Research, Inc.$47,325,954
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$38,382,452
- Martin Friedlander · Scripps Research Institute$36,319,942
Research focus
Drug Delivery SystemsPharmaceutical PreparationsIn VivoRetinaPropertyTissuesBlindnessVascular Endothelial Growth FactorsDiabetic RetinopathyOryctolagus CuniculusBackChoroidRetinal DiseasesAnimal ModelAreaDrug EfficacyScleraLipophilicityRouteAnimalsRetinal DetachmentEndophthalmitisBaseRattus
Grant awards (41)
Back of the eye drug delivery: Novel contact lenses, pathways, and in-silico modeling$468,554
R01 · FY2025 · EY
Nanobarrier contact lenses for mono and combination therapy for treating microbial keratitis$192,375
R21 · FY2025 · EY
Unidirectional delivery of heat to the eyelid by GoldInLens$191,653
R21 · FY2025 · EY
Back of the eye drug delivery: Novel contact lenses, pathways, and in-silico modeling$468,554
R01 · FY2024 · EY
Nanobarrier contact lenses for mono and combination therapy for treating microbial keratitis$243,325
R21 · FY2024 · EY
Unidirectional delivery of heat to the eyelid by GoldInLens$242,946
R21 · FY2024 · EY
Back of the eye drug delivery: Novel contact lenses, pathways, and in-silico modeling$481,429
R01 · FY2023 · EY
Nonivasive Monitoring of Suprachoroidal Delivery$194,375
R21 · FY2020 · EY · contact PI
Nonivasive Monitoring of Suprachoroidal Delivery$233,250
R21 · FY2019 · EY · contact PI
miRNA Regulation of Vascular Permeability and Inflammation in the Lung Injury$618,741
R01 · FY2017 · HL
miRNA Regulation of Vascular Permeability and Inflammation in the Lung Injury$614,883
R01 · FY2016 · HL
Suprachroidal Drug Delivery for Retina Disorders$529,926
R01 · FY2016 · EY · contact PI
Hybrid Nanoparticles for Glaucoma$422,454
R01 · FY2016 · EY
miRNA Regulation of Vascular Permeability and Inflammation in the Lung Injury$602,207
R01 · FY2015 · HL
Suprachroidal Drug Delivery for Retina Disorders$504,283
R01 · FY2015 · EY · contact PI
Hybrid Nanoparticles for Glaucoma$414,003
R01 · FY2015 · EY
miRNA Regulation of Vascular Permeability and Inflammation in the Lung Injury$620,850
R01 · FY2014 · HL
Suprachroidal Drug Delivery for Retina Disorders$566,727
R01 · FY2014 · EY · contact PI
Hybrid Nanoparticles for Glaucoma$448,704
R01 · FY2014 · EY
Transcleral Therapeutics in Diabetic Retinopathy$353,153
R01 · FY2014 · EY · contact PI
Suprachroidal Drug Delivery for Retina Disorders$656,290
R01 · FY2013 · EY · contact PI
In Vitro-In Vivo Correlation of Ocular Implants$565,405
U01 · FY2013 · FD · contact PI
Transcleral Therapeutics in Diabetic Retinopathy$376,531
R01 · FY2013 · EY · contact PI
Transcleral Therapeutics in Diabetic Retinopathy$499,000
R01 · FY2012 · EY · contact PI
Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavai$444,332
U01 · FY2012 · FD · contact PI
Transcleral Therapeutics in Diabetic Retinopathy$396,348
R01 · FY2012 · EY · contact PI
Transcleral Therapeutics in Diabetic Retinopathy$396,348
R01 · FY2011 · EY · contact PI
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside$33,880
R13 · FY2011 · EY · contact PI
Transcleral Therapeutics in Diabetic Retinopathy$425,447
R01 · FY2010 · EY · contact PI
Influence of eye pigmentation and diabetes on retinal drug delivery$408,038
R01 · FY2010 · EY · contact PI
Topical Nanoparticles for CNV$271,468
R41 · FY2010 · EY · contact PI
Influence of eye pigmentation and diabetes on retinal drug delivery$397,828
R01 · FY2009 · EY · contact PI
Delivery of LEDGF for retinal degenerative disorders$185,809
R21 · FY2008 · EY · contact PI
Delivery of LEDGF for retinal degenerative disorders$208,750
R21 · FY2007 · EY · contact PI
Pharmacological Approaches to Treat Diabetic Retinopathy$223,624
R01 · FY2005 · DK
Subconjunctival Route to Prolong Corticosteroid Delivery$147,000
R03 · FY2005 · EY
Pharmacological Approaches to Treat Diabetic Retinopathy$214,804
R01 · FY2004 · DK
Subconjunctival Route to Prolong Corticosteroid Delivery$147,000
R03 · FY2004 · EY
Pharmacological Approaches to Treat Diabetic Retinopathy$8,622
R01 · FY2004 · DK
Pharmacological Approaches to Treat Diabetic Retinopathy$249,533
R01 · FY2003 · DK
Subconjunctival Route to Prolong Corticosteroid Delivery$147,000
R03 · FY2003 · EY